• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非氮质血症肝硬化患者腹水利尿治疗阶梯式护理方法中对螺内酯无反应的病理生理学解释。

A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.

作者信息

Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C

机构信息

Department of Clinical Medicine, University of Padua, Italy.

出版信息

Hepatology. 1991 Aug;14(2):231-6.

PMID:1860680
Abstract

It has been hypothesized that the magnitude of proximal sodium reabsorption affects the response to aldosterone antagonists in nonazotemic cirrhotic patients with ascites. To verify this hypothesis, we evaluated intrarenal sodium handling by lithium clearance in 51 nonazotemic ascitic cirrhotic patients and in 23 controls who were maintained on the same low-sodium diet (80 mmol/day). Seven of 51 cirrhotic patients underwent spontaneous diuresis, whereas 44 required diuretic treatment. Treatment was started with spironolactone at a dose of 150 mg once daily. The dose was increased to 300 mg and then to 500 mg once daily if no response ensued. Cirrhotic patients who did not experience ascites mobilization with 500 mg spironolactone were then treated with a combined diuretic regimen that included spironolactone at a fixed dose (500 mg once daily) and furosemide at an initial dose of 50 mg once daily. The dose was increased to 100, 150 and 200 mg once daily if no response was noticed. Response to diuretic treatment was defined as body weight loss greater than 700 gm every 3 days until ascites became clinically undetectable. Nonresponders (43%) to spironolactone showed lower sodium fractional excretion (0.34% +/- 0.28% vs. 0.80% +/- 0.50%; p less than 0.001) because of a lower fractional sodium delivery to the distal tubule (18.2% +/- 5.8% vs. 23.4% +/- 7.2%; p less than 0.025) than responders.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

有假说认为,非氮质血症性肝硬化腹水患者近端钠重吸收的程度会影响其对醛固酮拮抗剂的反应。为验证这一假说,我们通过锂清除率评估了51例非氮质血症性肝硬化腹水患者及23例维持相同低钠饮食(80 mmol/天)的对照者的肾内钠处理情况。51例肝硬化患者中有7例出现自发性利尿,而44例需要利尿剂治疗。治疗起始给予螺内酯,剂量为每日150 mg一次。若没有反应,剂量增至每日300 mg,然后增至每日500 mg。对500 mg螺内酯无腹水消退反应的肝硬化患者,随后采用联合利尿剂方案治疗,该方案包括固定剂量(每日500 mg)的螺内酯和初始剂量为每日50 mg的呋塞米。若未观察到反应,剂量增至每日100、150和200 mg。利尿剂治疗的反应定义为每3天体重减轻超过700 g,直至腹水在临床上无法检测到。螺内酯治疗无反应者(43%)的钠排泄分数较低(0.34%±0.28%对0.80%±0.50%;p<0.001),因为其远端小管的钠输送分数较低(18.2%±5.8%对23.4%±7.2%;p<0.025)。(摘要截断于250字)

相似文献

1
A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.非氮质血症肝硬化患者腹水利尿治疗阶梯式护理方法中对螺内酯无反应的病理生理学解释。
Hepatology. 1991 Aug;14(2):231-6.
2
[Biological factors influencing response to diuretics in patients with cirrhosis and ascites].[影响肝硬化腹水患者对利尿剂反应的生物学因素]
Gastroenterol Clin Biol. 2001 Mar;25(3):268-72.
3
Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites.氨氯吡咪和螺内酯钾对非氮质血症肝硬化腹水患者疗效的随机临床研究
Hepatology. 1994 Jan;19(1):72-9.
4
Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.速尿诱导的利钠作用作为一种鉴别肝硬化难治性腹水患者的试验。
Hepatology. 2001 Jan;33(1):28-31. doi: 10.1053/jhep.2001.20646.
5
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.奥曲肽、利尿剂或两者联合治疗对非氮质血症肝硬化腹水患者门静脉血流动力学的影响。
J Clin Gastroenterol. 2006 Apr;40(4):342-6. doi: 10.1097/01.mcg.0000210101.74618.61.
6
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.可乐定对肝硬化腹水患者利尿反应及交感神经系统激活的影响。
Hepatology. 2006 Oct;44(4):844-9. doi: 10.1002/hep.21355.
7
Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.利尿剂、奥曲肽或两者联合治疗对非氮质血症肝硬化腹水患者的肾脏影响。
Nephrol Dial Transplant. 2005 Aug;20(8):1623-9. doi: 10.1093/ndt/gfh871. Epub 2005 May 10.
8
Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites.鉴别利尿剂无应答者与不良长期临床结局:176 例非氮质血症性肝硬化合并中等量腹水患者的 1 年随访。
Clin Sci (Lond). 2011 Dec;121(11):509-21. doi: 10.1042/CS20110018.
9
Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.影响非氮质血症肝硬化患者腹水利尿剂治疗反应的预测因素。
Scand J Gastroenterol. 1998 Apr;33(4):441-7. doi: 10.1080/00365529850171099.
10
Management of cirrhotic ascites.肝硬化腹水的管理
Clin Pharm. 1989 Sep;8(9):645-54.

引用本文的文献

1
Update on the Complications and Management of Liver Cirrhosis.肝硬化并发症与管理的最新进展
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
2
CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.克罗地亚门静脉高压诊断与治疗指南。
Acta Clin Croat. 2024 Apr;63(1):214-243. doi: 10.20471/acc.2024.63.01.26.
3
Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons.肝硬化腹水的药物治疗:从挑战到新兴治疗领域。
Gut Liver. 2024 Nov 15;18(6):934-948. doi: 10.5009/gnl240038. Epub 2024 Aug 29.
4
Review article: current and emerging therapies for the management of cirrhosis and its complications.综述文章:肝硬化及其并发症管理的当前及新兴疗法
Aliment Pharmacol Ther. 2022 May;55(9):1099-1115. doi: 10.1111/apt.16831. Epub 2022 Mar 2.
5
Medically tailored meals for the management of symptomatic ascites: the SALTYFOOD pilot randomized clinical trial.用于治疗症状性腹水的医学定制膳食:SALTYFOOD 试点随机临床试验
Gastroenterol Rep (Oxf). 2020 Nov 12;8(6):453-456. doi: 10.1093/gastro/goaa059. eCollection 2020 Dec.
6
Guidelines on the management of ascites in cirrhosis.肝硬化腹水管理指南。
Gut. 2021 Jan;70(1):9-29. doi: 10.1136/gutjnl-2020-321790. Epub 2020 Oct 16.
7
Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.茵陈蒿汤与螺内酯的药代动力学和药效学同时相互作用的临床前研究。
BMC Complement Med Ther. 2020 Aug 15;20(1):253. doi: 10.1186/s12906-020-03042-y.
8
Current management of uncomplicated ascites.单纯性腹水的当前管理。
Clin Liver Dis (Hoboken). 2013 Jun 21;2(3):125-127. doi: 10.1002/cld.193. eCollection 2013 Jun.
9
The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis.门诊临床护理对酒精性肝硬化患者生存率和住院率的影响
Radiol Oncol. 2017 Dec 7;52(1):75-82. doi: 10.1515/raon-2017-0056. eCollection 2018 Mar.
10
Management of ascites and hepatorenal syndrome.腹水和肝肾综合征的管理。
Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23.